Was worth the wait, sharing our real-world analysis of HER2 across solid tumors! 206750 tumors profiled by @carisls for ERBB2 alterations, revealing complex relationships between ERBB2 alterations and HER2 IHC expression. Forever grateful to @Dr_R_Kurzrock for her mentorship.
#ASCO26 Highlights from the New Targeted Therapies in Sarcoma session showcased the expanding treatment landscape for #GIST. With multiple new targeted therapies emerging & more options being studied in clinical trials, this is an exciting time for the GIST community.
Big conferences like #ASCO26 help shape the future of cancer care, and GIST is part of the conversation.
Here are some of the key #GIST research updates we’re watching.
@CogentBio Announces @FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with #GIST@SylvesterCancer@Liferaftgroup
https://t.co/4ycFYpA1Mt.
“Institutions are designed to endure beyond individuals. On the other hand, families are not….Medicine can have extraordinary meaning. But it cannot substitute for being present in your own life. The world may need us as physicians. But the people who love us need us as ourselves.”
Appreciate this profound and thoughtful @JAMA_current editorial by @jenna_taglienti on the importance of MD wellness and priorities- a MUST-READ for all physicians. Wishing you and your family the very best, Dr Taglienti :)
We're seeking a Life Sciences Contracts Attorney to help us accelerate chordoma therapy development. If you're an experienced attorney who'd enjoy being embedded within a patient-driven research and drug development organization (or if you know others who may be interested), please apply or spread the word! Details: https://t.co/PXeCLFOsOy
Basket trial of the EZH2 inhibitor tazemetostat demonstrated preliminary antitumor activity with responses in rhabdoid tumors, INI1-negative tumors and poorly differentiated chordomas. No responses seen in synovial sarcoma and renal medullary carcinoma. https://t.co/7Mv2foVRGZ
Ipsen announced the voluntary withdrawal of tazemetostat from all global markets and for all indications, effective immediately. This decision follows a recommendation from the IDMC based on emerging safety data from the phase 1b/3 SYMPHONY-1 trial. https://t.co/OZ4xCeAsIk